$MRNA · Moderna, Inc.

Moderna filed an 8-K announcing the creation of a Chief Operating Officer role and the appointment of Juan Andres, effective October 5, 2026. Andres previously served at Moderna from 2017–2023, including as Chief Technical Operations and Quality Officer, where he led the manufacturing scale-up of the COVID-19 vaccine. The new COO role comes as Moderna prepares for the potential launch of intismeran autogene (jointly developed with Merck) following positive Phase 3 results. Concurrently, Jerh Collins, Chief Technical Operations and Quality Officer, is retiring. Andres will receive an $800,000

Extended-hours trading shows MRNA at $189.62, down 6.80% from the regular-session close of $203.46. The after-hours decline suggests the market is reacting cautiously to the leadership reshuffle, though the move may also reflect broader biotech sentiment given no regular-session trading has occurred since the filing.

Moderna is restructuring its C-suite ahead of its most important pipeline transition since COVID — moving from vaccines into oncology with the intismeran autogene launch.

Moderna's creation of a COO role mirrors a common biotech maturation pattern as companies transition from R&D-focused to commercial-scale operations, particularly ahead of a major oncology launch. The rehiring of a former manufacturing executive signals prioritization of operational execution over R

The press release notes forward-looking risks including uncertainties around the launch and scale-up of intismeran autogene, execution of the oncology portfolio, and the broader risks detailed in Moderna's 2025 10-K. The COO role is newly created, adding execution risk around role definition and the